Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) Gross Profit: 2012-2025

Historic Gross Profit for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $93.1 million.

  • CorMedix's Gross Profit rose 764.30% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.5 million, marking a year-over-year increase of 1839.33%. This contributed to the annual value of $40.3 million for FY2024, which is 117552.87% up from last year.
  • Latest data reveals that CorMedix reported Gross Profit of $93.1 million as of Q3 2025, which was up 145.76% from $37.9 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Gross Profit registered a high of $93.1 million during Q3 2025, and its lowest value of -$818,539 during Q1 2024.
  • Moreover, its 3-year median value for Gross Profit was $5.5 million (2024), whereas its average is $20.9 million.
  • Examining YoY changes over the last 5 years, CorMedix's Gross Profit showed a top increase of 82,228.55% in 2024 and a maximum decrease of 9,227.02% in 2024.
  • Quarterly analysis of 5 years shows CorMedix's Gross Profit stood at $8,390 in 2021, then skyrocketed by 249.18% to $29,296 in 2022, then tumbled by 345.19% to -$13,113 in 2023, then spiked by 82,228.55% to $30.0 million in 2024, then skyrocketed by 764.30% to $93.1 million in 2025.
  • Its last three reported values are $93.1 million in Q3 2025, $37.9 million for Q2 2025, and $37.5 million during Q1 2025.